Search Results for ''

published presentations and documents on DocSlides.

Optimizing  the frequency of kidney safety monitoring in HIV-uninfected persons using daily oral te
Optimizing the frequency of kidney safety monitoring in HIV-uninfected persons using daily oral te
by groundstimulus
PrEP. Kenneth Mugwanya, . Renee Heffron. , Christi...
Comparison of INSTI vs INSTI
Comparison of INSTI vs INSTI
by mediumgeneral
QDMRK. SPRING-2. ONCEMRK. GS-US-380-1489. GS-US-38...
Update on  the  observational study
Update on the observational study
by limelighthyundai
on short . MDRTB . regimen. Valérie Schwoebel. Th...
Infant  clinical considerations
Infant clinical considerations
by pressio
IMPAACT 2010 study-specific Training. May 2017. 1....
Uganda  Sickle  Survey Results and  Neonatal Screening Program
Uganda Sickle Survey Results and Neonatal Screening Program
by adhesivedisney
. Charles Kiyaga. National Sickle Cell Coordinator...
Switch  from  TDF to TAF
Switch from TDF to TAF
by easyho
GS-US-292-0109 Study. GS-US-311-1089 Study. . De...
Comparison of INSTI  vs  EFV
Comparison of INSTI vs EFV
by mediumgeneral
STARTMRK. GS-US-236-0102 . SINGLE. Walmsley. S. N...
Public  expenditure on drug treatment and associated comorbidities: a case study of Bergamo
Public expenditure on drug treatment and associated comorbidities: a case study of Bergamo
by alexa-scheidler
Public expenditure on drug treatment and associa...
Efficacy and Safety of
Efficacy and Safety of
by olivia-moreira
Efficacy and Safety of Glecaprevir / Pibrentasvi...
C-EDGE  Co-Infected: Phase 3 Study of
C-EDGE Co-Infected: Phase 3 Study of
by giovanna-bartolotta
C-EDGE Co-Infected: Phase 3 Study of Grazoprevi...
Dolutegravir  monotherapy
Dolutegravir monotherapy
by alexa-scheidler
Dolutegravir monotherapy vs. dolutegravir/ abac...
PrEP Considerations for HPX3002/HVTN 706
PrEP Considerations for HPX3002/HVTN 706
by tatyana-admore
PrEP Considerations for HPX3002/HVTN 706 Susan Bu...
1 Patria Rojas, Ph.D., M.P.H., M.S.W.
1 Patria Rojas, Ph.D., M.P.H., M.S.W.
by celsa-spraggs
Frank R. Dillon, Ph.D. .. Center . for Research ....
Comparison of NNRTI vs NNRTI
Comparison of NNRTI vs NNRTI
by lindy-dunigan
ENCORE. EFV vs RPV. ECHO-THRIVE. STAR. EFV vs ETR...
Switch to INSTI   NNRTI Switch to DTG   RPV
Switch to INSTI NNRTI Switch to DTG RPV
by trish-goza
SWORD. . Study. Switch to CAB LA RPV LA IM. LA...
Evidence based practices for retention in care of mother infant pairs in the context of PMTCT in
Evidence based practices for retention in care of mother infant pairs in the context of PMTCT in
by lois-ondreau
ESA: . A summary with guidance for scale up. Phil...
Qualitative Methods in M&E of HIV and AIDS
Qualitative Methods in M&E of HIV and AIDS
by ellena-manuel
programme. (UP Lecture . 2011). Prof. . Supa. . ...
Protocol Requirements for Product Holds/Discontinuations
Protocol Requirements for Product Holds/Discontinuations
by yoshiko-marsland
MTN-025. Objectives. Identify the conditions that...
MTN-037 Screening and Enrollment
MTN-037 Screening and Enrollment
by giovanna-bartolotta
SSP Manual References. Protocol Sections 7.2 (Scr...
Evidence based practices for retention in care of mother infant pairs in the context of PMTCT in
Evidence based practices for retention in care of mother infant pairs in the context of PMTCT in
by jane-oiler
ESA: . A summary with guidance for scale up. Phil...
Modifying Therapy in the Treatment-experienced Patient:
Modifying Therapy in the Treatment-experienced Patient:
by yoshiko-marsland
When should it be done?. Professor of Medicine. U...
Protocol Requirements for Product Holds/Discontinuations
Protocol Requirements for Product Holds/Discontinuations
by tatiana-dople
MTN-025. Objectives. Identify the conditions that...
Fixed-Dose Combination of
Fixed-Dose Combination of
by myesha-ticknor
Doravirine. /Lamivudine/TDF is Non-Inferior to . ...
PEG alfa-2a    RBV  versus
PEG alfa-2a RBV versus
by alexa-scheidler
. PEG alfa-. 2a . versus. INF RBV . APRICOT S...
Why did it help or not help? Utilizing
Why did it help or not help? Utilizing
by kittie-lecroy
qualitative data to understand the results of . a...
Self-Study Modules  on Tuberculosis, 1-5
Self-Study Modules on Tuberculosis, 1-5
by test
Centers for Disease Control and Prevention. Divis...
Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine
Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine
by luanne-stotts
Chief, Division of Infectious Diseases. Weill Med...
Evaluation of tolerability, pharmacokinetics, and anti-
Evaluation of tolerability, pharmacokinetics, and anti-
by pamella-moone
r. etroviral activity of MK-8591 in treatment-na...
Switch to EVG/c/FTC/TDF
Switch to EVG/c/FTC/TDF
by liane-varnes
STRATEGY-PI . Study. STRATEGY-NNRTI . Study. Desi...
Switch to INSTI + NNRTI
Switch to INSTI + NNRTI
by giovanna-bartolotta
Switch to DTG + RPV. SWORD. . Study. Switch to C...
Switch to E/C/F/TAF + DRV
Switch to E/C/F/TAF + DRV
by lindy-dunigan
Study GS-US-292-0119. E/C/F/TAF + DRV 800 mg QD. ...
NRTI-sparing
NRTI-sparing
by liane-varnes
SPARTAN. PROGRESS. RADAR. NEAT001/ANRS 14. 3. A40...
Who Benefited Most From Immediate Treatment in START
Who Benefited Most From Immediate Treatment in START
by lois-ondreau
A Subgroup Analysis. JM Molina, B . Grund. , F Go...
Comparison of NNRTI vs PI/r
Comparison of NNRTI vs PI/r
by alexa-scheidler
EFV vs LPV/r vs EFV + LPV/r . A5142. Mexican. . ...